血浆激肽释放酶抑制剂作为糖尿病性黄斑水肿、视网膜静脉阻塞、遗传性血管性水肿及其他相关疾病的潜在治疗方法。
Plasma Kallikrein Inhibitors as Potential Treatment for Diabetic Macular Edema, Retinal Vein Occlusion, Hereditary Angioedema and Other Related Diseases.
作者信息
Abdel-Magid Ahmed F
机构信息
Therachem Research Medilab, LLC, 100 Jade Park, Chelsea, Alabama 35043, United States.
出版信息
ACS Med Chem Lett. 2023 Jan 17;14(2):129-130. doi: 10.1021/acsmedchemlett.2c00526. eCollection 2023 Feb 9.
The invention in this patent application relates to ()-spiro[benzo[][1,3]oxazine-4,3'-pyrrolidin]-2(1)-one derivatives, represented generally by formula 1. These compounds are selective plasma kallikrein inhibitors and may potentially be beneficial in the treatment of several diseases and disorders, including hereditary angioedema, uveitis, posterior uveitis, wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion.
本专利申请中的发明涉及通式1一般表示的（）-螺[苯并[][1,3]恶嗪-4,3'-吡咯烷]-2(1)-酮衍生物。这些化合物是选择性血浆激肽释放酶抑制剂，可能对治疗多种疾病和病症有益，包括遗传性血管性水肿、葡萄膜炎、后葡萄膜炎、湿性年龄相关性黄斑变性、糖尿病性黄斑水肿、糖尿病性视网膜病变和视网膜静脉阻塞。
Zotero 插件